Page 1,292«..1020..1,2911,2921,2931,294..1,3001,310..»

Genetics reveal Pacific subspecies of fin whale | South County News – Chinook Observer

Posted: November 2, 2019 at 1:41 am

New genetic research has identified fin whales in the northern Pacific Ocean as a separate subspecies, reflecting a revolution in marine mammal taxonomy as scientists unravel the genetics of enormous animals otherwise too large to fit into laboratories.

"The increasing study of cetacean genetics is revealing new diversity among the world's whales and dolphins that has not been previously recognized," said Eric Archer, a geneticist at NOAA Fisheries' Southwest Fisheries Science Center (SWFSC) in La Jolla, California. Archer is the lead author of the identification of the new subspecies of fin whale.

"There's definitely more diversity out there than has been on the books," he said. "There has been a wave of progress in cetacean taxonomy."

Fin whales are the second-largest whale on earth and the fastest whales in the ocean, which made them one of the last whale species hunted to the edge of extinction. Whalers killed about 46,000 fin whales in the North Pacific Ocean from 1947 to 1987. They are also one of the least known large whale species. They mainly roam the open ocean, farther from coastlines where they might be seen and studied more easily. They have been observed off the south Washington coast.

Scientists from NOAA Fisheries, Ocean Associates Inc., Cascadia Research Collective, Tethys Research Institute, and Universidad Autnoma de Baja California Sur, identified the new subspecies. Their findings were published in an article in the Journal of Mammalogy, naming it Balaenoptera physalus velifera, which means "carrying a sail" in Latin.

"We don't get a lot of (genetic) material from them," Archer said. However, advancing technologies allowed Archer and his colleagues to extract the detail they needed from samples at the SWFSC. The center's Marine Mammal and Turtle Molecular Research Sample Collection is one of the largest collections of marine mammal genetic material in the world. They obtained additional samples from museums and other collections.

Traditional taxonomy the division of biological variation into recognized species and subspecies involves comparing telltale parts of the skeleton such as the skull. For whales, this may weigh hundreds of pounds. Few institutions can amass a large enough collection to compare different individuals from around the world.

"Fin whales measure 60 to 70 feet long and their skulls are around 15 feet long," Archer said. "Just housing a couple takes a lot of room."

Increasingly powerful genetic technologies now allow scientists to compare genes instead of skeletons. They extract DNA from tissue samples the size of a pencil eraser obtained from whales in the field.

"It's the only realistic way to do this, because you cannot get enough examples to determine the difference through morphology alone," Archer said. As they have looked more closely at the genetic patterns of whales around the world, scientists have discovered much more complex differences between them.

"Instead of digging through museum storage facilities for skulls to describe species or subspecies, genetic data unlock our ability to describe unique populations of whales across the globe," said research biologist Barbara Taylor, leader of the SWFSC's Marine Mammal Genetics Program. "It is a new way of looking at these animals."

Comparing the DNA from fin whales in the Pacific and the Atlantic oceans showed the scientists that they have been separated for hundreds of thousands of years. They also could assign individual fin whale samples to their ocean of origin using the genetic data. This is further evidence that they are separate and distinct subspecies.

Genetic research by NOAA Fisheries scientists has also revealed new details of other whales, including a new species of Baird's beaked whale. It may also help determine whether a recently documented type of killer whale off South America represents a new species.

Similar genetic details can also help tailor protections for threatened or endangered whales, because the Endangered Species Act recognizes separate subspecies. That means that managers can target ESA safeguards for those subspecies that need it even when others may have recovered. This could make conservation efforts more efficient and effective.

About 14,000 to 18,000 fin whales in the northern Pacific Ocean will be affected by the new subspecies designation. NOAA Fisheries has documented that their numbers are increasing.

"There are other new species and subspecies that we are learning about thanks to the technology that has made this possible," Archer said. "It is changing the field."

Read more:
Genetics reveal Pacific subspecies of fin whale | South County News - Chinook Observer

Posted in Genetics | Comments Off on Genetics reveal Pacific subspecies of fin whale | South County News – Chinook Observer

Weird butterfly genetics counter popular theory of evolution – Inverse

Posted: November 2, 2019 at 1:41 am

Evolution is generally thought of as a linear process: Species split off from one another over time, move to different places, and adapt different traits. But species like those in the Heliconius genus make patterns of evolution more interesting.

We need to take into account in our evolutionary models that we can get gene flow between species, Edelman says.

Heliconius made sense to study because of its hybrid-making tendencies. Its also just a cool really insect. The adult Heliconius eats pollen, which no other butterfly does. And Heliconius is smart, Edelman says. It has a home range, meaning it will go to visit the same flower every day, a habit more commonly associated with mammals.

The findings have potential implications for conservation and preserving pollinator populations. Studies show that species variation is key to protecting those populations in a changing climate.

One good thing about genetic diversity is if you have a really variable and diverse population, when environmental conditions change, you have a better chance of responding to them, Edelman says.

So how does hybridization factor in? Researchers dont all agree on whether its likely to contribute to genetic diversity. But it very well might.

Its at least somewhat likely that youre going to increase your variation rather than decrease it, Edelman says.

Conservation can involve protecting species by keeping out its close relatives, to avoid hybridization or a species takeover, but for species like these butterflies, that strategy may not work as well.

Hybridization is pretty common in nature, Edelman says. In some cases it might be good to bring in other species and increase genetic diversity for conservation purposes.

Visit link:
Weird butterfly genetics counter popular theory of evolution - Inverse

Posted in Genetics | Comments Off on Weird butterfly genetics counter popular theory of evolution – Inverse

Global Genetic Testing Markets 2020-2024 | by Hereditary, Newborn, NIPT, Oncology, Pharmacogenomic & Direct to Consumer – ResearchAndMarkets.com -…

Posted: November 2, 2019 at 1:41 am

DUBLIN--(BUSINESS WIRE)--The "The Global Genetic Testing Market by Hereditary, Newborn, NIPT, Oncology, Pharmacogenomic and Direct to Consumer, With Executive and Consultant Guides 2020 to 2024" report has been added to ResearchAndMarkets.com's offering.

This report forecasts the market size out to 2024. The report includes detailed breakouts for 14 countries and 5 regions.

Will all newborns receive Whole Genomic Sequencing at birth? What key interest is driving Direct to Consumer?

The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating a new life for the industry.

Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find opportunities and pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

All report data is available in Excel format on request

Key Topics Covered

1. Introduction and Market Definition

1.1 Genetic Testing Definition in This Report

1.2 The Genomics Revolution

1.3 Market Definition

1.3.1 Revenue Market Size

1.4 U.S. Medical Market and laboratory Testing - Perspective

1.4.1 U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

2.1 Market Participants Play Different Roles

2.1.1 Supplier/pharmaceutical

2.1.2 Independent lab specialized/esoteric

2.1.3 Independent lab national/regional

2.1.4 Independent lab analytical

2.1.5 Public National/regional lab

2.1.6 Hospital lab

2.1.7 Physician lab

2.1.8 DTC Lab

2.1.9 Independent Genetic Testing Lab

2.1.10 Audit Body

2.2 Genetic Tests -Types, Examples and Discussion

2.2.1 Preimplantation Genetic Diagnosis- An Emerging Market

2.2.2 Prenatal Diagnosis - New Technologies Create Opportunity

2.2.3 Newborn Screening

2.2.2 Diagnostic Testing

2.2.3 Carrier Testing

2.2.6 Predictive and Presymptomatic Testing

2.2.7 Pharmacogenomics

2.2.8 Forensic Testing

2.2.9 Parental Testing

2.2.10 Ancestral Testing

2.3 Industry Structure

2.3.1 Hospital's Testing Share

2.3.2 Economies of Scale

2.3.2.1 Hospital vs. Central Lab

2.3.3 Physician Office Lab's

2.3.4 Physician's and POCT

2.4 Market Shares of Key Genetics Players - Analysis

3. Market Trends

3.1 Factors Driving Growth

3.1.1 Genetic Discoveries Creating New Diagnostic Markets

3.1.2 Aging Population a Boon for Diagnostics

3.1.3 Pharmacogenomics Drives Further Growth

3.1.4 Oncology and Liquid Biopsy Enter New Era

3.1.5 Fertility Practice Growth drives market

3.1.6 Direct to Consumer begins to break out

3.2 Factors Limiting Growth

3.2.1 Increased Competition Lowers Price

3.2.2 Lower Costs

3.2.3 Testing usage analysis curtailing growth

3.2.4 Wellness has a downside

3.3 Instrumentation and Automation

3.3.1 Instruments Key to Market Share

3.3.2 Bioinformatics Plays a Role

3.4 Diagnostic Technology Development

3.4.1 Next Generation Sequencing Fuels a Revolution

3.4.2 Impact of NGS on pricing

3.4.3 POCT/Self Testing Disruptive Force

3.4.4 Pharmacogenomics Blurs Diagnosis and Treatment

3.4.5 CGES Testing, A Brave New World

3.4.6 Biochips/Giant magnetoresistance based assay

4. Genetic Testing Recent Developments

4.1.1 Importance of This Section

4.1.2 How to Use This Section

5. Profiles of Key Companies

6. Global Market Size

6.1 Global Market by Country

6.2 Global Market by Application

7. Market Sizes by Application

7.1 Hereditary Testing Market

7.2 Newborn Testing Market

7.3 NIPT Testing Market

7.4 Oncology Testing Market

7.5 Pharmacogenomic Testing Market

7.6 Direct to Consumer Testing Market

8. The Future of Genetic Testing

For more information about this report visit https://www.researchandmarkets.com/r/2llelf

View post:
Global Genetic Testing Markets 2020-2024 | by Hereditary, Newborn, NIPT, Oncology, Pharmacogenomic & Direct to Consumer - ResearchAndMarkets.com -...

Posted in Genetics | Comments Off on Global Genetic Testing Markets 2020-2024 | by Hereditary, Newborn, NIPT, Oncology, Pharmacogenomic & Direct to Consumer – ResearchAndMarkets.com -…

GPs urged to inform women about pre-pregnancy genetic testing – The Age

Posted: November 2, 2019 at 1:41 am

This is concerning, the study's lead researcher Dr Ruth Leibowitz said, because GPs are the first point of call for most pregnant women and those seeking preconception medical care.

Loading

"One theory is that GPs simply dont really know about the tests and the majority of these tests are being driven by patients requesting it," Dr Leibowitz said during a presentation of her findings at the GP19 conference in Adelaide last Friday.

When prenatal testing shows a fetus is at risk, families are faced with a profound and difficult decision on whether to keep the baby or terminate the pregnancy.

Many couples who are found to be carriers of the mutations prior to pregnancy can use IVF in conjunction with genetic testing of embryos to avoid having a child with a genetic condition.

Of the 21,172 women screened, one in 20 were carriers for at least one of the severe genetic disorders.

About 70 per cent were in the highest socio-economic quartile as measured by residential postcode. About 53 per cent were pregnant at the time of screening.

Earlier this year, the Royal Australian and New Zealand College of Obstetricians and Gynaecologists set new guidelines, recommending that all women planning a pregnancy or in their first trimester should be given information about preconception carrier screening.

But Professor Martin Delatycki, clinical director of the Victorian Clinical Genetics Services and member of the Genomics Advisory Working Group, estimates less than 10 per cent of aspiring parents are offered such screening.

Loading

"What the results show us is that GPs are in an ideal position to offer it because they see women before they are pregnant," Professor Delatycki said.

"When women are not pregnant and they have screening, they have much more time to make a decision if theyre at high risk of having a child with one of the genetic conditions.

"It is very critical its a choice for people, not just a routine test," he said. "Because its not right for everybody.

Royal Australian College of General Practitioners president Harry Nespolon argued the onus should be on obstetricians with the expertise to discuss genetic testing with would-be parents, with many GPs choosing to refer women on to genetic counsellors.

For some patients, testing for the rare conditions went against their belief system, Dr Nespolon said.

"This is not a decision to be taken lightly because there is a lot to consider about requesting genetic screening, ultimately it can affect patients pyschologically and financially. It can affect people quite deeply and the choices they make."

Carrier screening to determine if couples carry the mutations for SMA, cystic fibrosis and fragile X is not routinely offered and many doctors do not know the tests exist.

Loading

Professor Delatycki said recent research pointed to women having a higher chance of having a baby with one of the three genetic conditions, than there is of having a baby with Down Syndrome.

The tests can cost up to $1800 for couples and are not covered by Medicare, prompting concerns that only wealthy aspiring parents can take this precaution in a bid to avoid having a baby with a severe genetic condition.

Fragile X syndrome causes intellectual disability and behavioural and learning challenges, and is also the most common single-gene cause of autism worldwide. Spinal muscular atrophy is a severe muscle-wasting disease, while cystic fibrosis damages the lungs and digestive system.

The landmark Mackenzie's Mission trial has begun recruiting 10,000 Australian couples to be screened for 500 severe and deadly genetic conditions.

The results of the trial are expected to inform whether the federal government will introduce Medicare subsidies for carrier screening.

Melissa Cunningham is The Age's health reporter.

Continue reading here:
GPs urged to inform women about pre-pregnancy genetic testing - The Age

Posted in Genetics | Comments Off on GPs urged to inform women about pre-pregnancy genetic testing – The Age

Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting – BioSpace

Posted: November 2, 2019 at 1:41 am

SALT LAKE CITY, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that three studies on Vectra will be featured at the 2019 American College of Rheumatology (ACR) Annual Meeting being held Nov. 8-13, 2019 in Atlanta, GA.

"We are excited to share important new data that demonstrates how precision medicine can advance care for people with rheumatoid arthritis (RA)," said Elena Hitraya, M.D., Ph.D., rheumatologist and chief medical officer at Myriad Autoimmune. "Our studies show that Vectra, an objective measure of RA inflammation, helps identify people with RA that are at risk of joint damage and cardiovascular risk.

A list of presentations at 2019 ACR is below. Please visit Myriad Autoimmune at booth #1419 to learn more about Vectra. Follow Myriad on Twitter via @myriadgenetics and follow meeting news by using the hashtag #ACR19.

Abstract

Author

Poster Details

Vectra

Predicting Risk of Radiographic Progression for Patients with Rheumatoid Arthritis

Jeffrey Curtis

Joshua Baker

Jeffrey Curtis

About VectraVectra is a multi-biomarker molecular blood test that provides an objective and personalized measure of inflammatory disease activity in patients with rheumatoid arthritis. Vectra provides unsurpassed ability to predict radiographic progression and can help guide medical management decisions with the goal of improving patient outcomes. Vectra testing is performed at a state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are reported to the physician five to seven days from shipping of the specimen. Physicians can receive test results by fax or the private web portal, VectraView. For more information on Vectra, please visit: http://www.vectrascore.com.

About Myriad GeneticsMyriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to data being presented for its genetic tests at the American College of Rheumatology Annual Meeting being held Nov. 8-13, 2019 in Atlanta, GA; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Follow this link:
Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting - BioSpace

Posted in Genetics | Comments Off on Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting – BioSpace

Three UCLA scientists receive grants totaling more than $18 million – Newswise

Posted: October 31, 2019 at 6:45 pm

MEDIA CONTACT

Available for logged-in reporters only

Newswise Three researchers at theEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLAhave received awards totaling more than $18 million from the California Institute for Regenerative Medicine, the states stem cell agency.

The recipients are Dr. Sophie Deng, professor of ophthalmology at the UCLA Stein Eye Institute;Yvonne Chen, a UCLA associate professor of microbiology, immunology and molecular genetics; and Dr. Caroline Kuo, a UCLA assistant clinical professor of pediatrics. The awards were announced at a CIRM meeting today.

Dengs four-year, $10.3 million award will fund a clinical trial for a blinding eye condition called limbal stem cell deficiency. Limbal stem cells are specialized stem cells in eye tissue that help maintain the health of the cornea. Because of genetic defects or injuries caused by infections, burns, surgeries or other factors, some people do not have enough limbal stem cells, which results in pain, corneal scarring and blindness.

The approach she is testing involves extracting a small number of limbal stem cells from a persons eye, multiplying them in a lab, and then transplanting them back into the eye, where they could regenerate the cornea and restore vision. The research will be conducted in collaboration with theUCLAUCI Alpha Stem Cell Clinic, a partnership between UCLA and UC Irvine.

The grants awarded to Chen and Kuo are for projects that are heading toward the FDAs investigational new drug application process, which is required by the agency before a phase 1 clinical trial the stage of testing that focuses on a treatments safety.

Chens two-year, $3.2 million award will fund efforts to create a more effectiveCAR T cell therapyfor multiple myeloma, a blood cancer that affects white blood cells. The research will evaluate a specialized form of CAR T therapy that simultaneously targets two markers, BCMA and CS1, commonly found on multiple myeloma cells. CAR T therapies that target BCMA alone have been effective in clinical trials, but the presence of BCMA on multiple myeloma cells is not uniform.

Previous research has shown that the marker CS1 is present in around 90% of multiple myeloma cells. A CAR T therapy that targets both markers could potentially help more patients and reduce the likelihood of a cancer relapse.

Kuos 2 1/2-year, $4.9 million award, will support the development of a stem cell gene therapy for a deadly immunodeficiency called X-linked hyper IgM syndrome, or XHIM.

The syndrome, which is caused by a mutation in the CD40LG gene, results in invasive infections of the liver, gastrointestinal tract and lungs. Currently, the only potential cure is a bone marrow transplant from a matched donor, which carries life-threatening risks and is often less effective for XHIM patients than patients with other forms of immune deficiency. Even with current treatments, only 30% of people with the syndrome live to age 30.

Kuo will evaluate a stem cell gene therapy that corrects the genetic mutation that causes XHIM. After removing blood-forming stem cells from a person with the syndrome, the therapy would use a genetic engineering technique called CRISPR to insert a correct copy of the affected gene into the DNA of the stem cells. The corrected blood-forming stem cells would be infused back into the patient, where they could regenerate a healthy immune system.

She will collaborate with Dr. Donald Kohn, a UCLA distinguished professor of microbiology, immunology and molecular genetics who has successfully treated two other immune deficiencies bubble baby disease and X-linked chronic granulomatous disease with a similar therapy.

Read more:
Three UCLA scientists receive grants totaling more than $18 million - Newswise

Posted in Stem Cells | Comments Off on Three UCLA scientists receive grants totaling more than $18 million – Newswise

Stem Cell Research and Hair Transplants How Far Have We Come? – Science Times

Posted: October 31, 2019 at 6:45 pm

(Photo : Stem cell research and hair transplants how far have we come?)

We all know that hair loss is a major problem, particularly for men around the world. While men who have enough hair left can have hair transplant procedures such as the FUT, FUE or DHI, done, this is not always possible.

It is always a smart move to consult with a hair loss specialist regardless of your situation because they may still be able to suggest something if you still have some hair. Only the specialist can tell assess what your situation is and what options are available. You can, for example, always contact a specialist at the Vera Clinic in Turkey to get evaluated.

In fact, men who are already very bald and have lost most of the hair found in the donor areas such as the back of the head may be out of luck when it comes to being able to have transplant surgery. This is a reason that scientists have been conducting experiments using stem cells. Some types of stem cells can be used to regenerate other types of cells and tissues in the body, so it is only natural that the idea came about to use stem cells to grow new hair follicles.

Stem cell research

There is often a lot of controversy regarding stem cell research because many people, including politicians, think that only human fetuses have stem cells and thus they argue that it is an unethical area of research. However, everybody has stem cells, not just fetuses, and it is a person's own stem cells that hold the potential to make new tissues. This is also partly why PRP therapy has been so successful, because the plasma actually contains many stem cells which trigger growth and repair of tissues.

Researchers have been able to grow some human hair follicles in the laboratory using stem cells. These same hairs were then transplanted into a mouse. Human testing cannot begin until animal testing is completed and many countries have rigorous processes in place when it comes to scientific investigations in humans.

This means that we can expect it to be some time yet before any human trials can take place using stem cells and hair transplants from follicles that are grown in the lab. The other problem which the scientists have noted is that it is more complicated than it seems since even though hair was transplanted into the mice, the outcome was not good and the hair was found to grow at odd angles. This could have been because it was a transplant between different species, but the reality is that hair transplantation is not as simple as it seem.

Stem cells may, however, be the last chance for people who have lost most of their hair. Scientists think that autologous hair transplants based on growing hair from a person's own stem cells may be something that becomes a reality in the future. At the moment, more studies need to be undertaken and the best advice is to seek treatment for hair loss before it reaches a point where nothing can be done.

Continued here:
Stem Cell Research and Hair Transplants How Far Have We Come? - Science Times

Posted in Stem Cells | Comments Off on Stem Cell Research and Hair Transplants How Far Have We Come? – Science Times

Exosome Procedures Now Being Included With the R3 Stem Cell Regenerative Aesthetics Training Course – Yahoo Finance

Posted: October 31, 2019 at 6:45 pm

R3 Stem Cell, the nation's leader in regenerative medicine training, is now including exosome procedures in its regenerative aesthetics courses. There are still spots remaining for the November 15-16th, 2019 course in Scottsdale, Arizona.

SCOTTSDALE, Ariz., Oct. 31, 2019 /PRNewswire-PRWeb/ --R3 Stem Cell, the nation's leader in regenerative medicine training, is now including exosome procedures in its regenerative aesthetics courses. There are still spots remaining for the November 15-16th, 2019 course in Scottsdale, Arizona. Visit https://stemcelltrainingcourse.org/aesthetics or call (844) GET-STEM to register.

Exosomes are a huge buzzword in regenerative medicine and with good reason. Scientists and clinicians have found them to be extremely powerful at harnessing the body's repair processes.

At the R3 Stem Cell Regenerative Aesthetics Course, providers learn leading techniques for hair restoration, facial rejuvenation and ED. The training is hands on, including real patients and real biologics such as PRP therapy, stem cells and exosomes as well.

According to R3 CEO David Greene, MD, MBA, "Exosome therapy has been a very exciting addition to regenerative medicine. At our courses providers get hands on experience using them and also having procedures performed on them. That's the key in becoming the local leader in regenerative aesthetics!"

R3 Stem Cell has first rate trainers who have performed thousands of regenerative cases for hair restoration, facial rejuvenation and sexual health. In conjunction with fillers and PDO Threadlifts, the procedures have been amazing for patients looking and feeling younger.

Added Dr. Greene, "Compared with a surgery such as tummy tuck, facelift or hair grafting, these procedures involve no downtime, minimal risk and are much more cost effective. But they do require hands on training, and our courses provide a first rate experience!"

For the past eight years, R3's network of practices nationally have performed over 12,000 stem cell procedures and over 50,000 PRP therapies. The training courses have incorporated the best practice protocols and first rate biologics so providers receive training that immediately translates into practice.

There are presentations on sales and marketing along with "need to know" information on stem cells, exosomes and PRP biologics and how they work. Everything necessary to acquire patients, convert them to procedures and perform them is taught.

Spots are limited at the regenerative aesthetics training courses. Providers that will benefit from the training include MD, DO, RN, PA, NP and aesthetician injectors. Call (844) GET-STEM for registration, which is currently $1000 off.

See the original post:
Exosome Procedures Now Being Included With the R3 Stem Cell Regenerative Aesthetics Training Course - Yahoo Finance

Posted in Stem Cells | Comments Off on Exosome Procedures Now Being Included With the R3 Stem Cell Regenerative Aesthetics Training Course – Yahoo Finance

Stem cell therapy approved for MS patients in Scotland – HeraldScotland

Posted: October 31, 2019 at 6:45 pm

MULTIPLE sclerosis campaigners have hailed a huge step forward for patients in Scotland after a stem cell therapy was recommended for use on the NHS for the first time.

Haematopoietic stem cell transplantation (HSCT) has been described as a game-changer for MS after an international clinical trial showed that it could reboot patients immune systems and halt the progress of the disease.

Some patients who had been in wheelchairs prior to treatment said their condition improved so dramatically it was like they had never been diagnosed with MS.

READ MORE: Scots MS patients 'missing out' on pioneering stem cell treatment available in England

The Scottish Health Technologies Group (SHTG) said there is now sufficient evidence for it to recommend making HSCT available on the NHS in Scotland to MS patients who have the relapsing-remitting form of the disease, and who were not responding to drug treatments.

Iain Robertson, chairman of the SHTG, said: Our committee members were able to advise that this treatment should be considered for those with this particular type of MS who have not responded to treatment with disease-modifying therapies.

We hope that our advice will be of use in helping decide the best course of treatment for these patients.

The SHTG also stressed that patients must be made aware of the demands, risks and uncertainties of the treatment, which uses chemotherapy to wipe out patients' 'faulty' immune systems before replenishing it with a transplant of stem cells harvested from their own bone marrow.

It puts patients at high risk from infections, which can be fatal, but the theory is that the treatment works by enabling patients to 'reset' their immune system to stop it attacking the central nervous system as is the case in MS.

READ MORE: Anger of Scots MS patients travelling abroad for stem cell therapy available to some on NHS England

HSCT is not considered an effective treatment for patients with the progressive form of MS, however, as stem cells cannot regrow nerves or repair damaged myelin - the protective sheath which coats nerves.

It will also be unavailable to patients with relapsing-remitting MS who no longer show signs of inflammation on an MRI brain scan.

Scotland has one of the highest rates of MS in the world, but until now Scottish patients seeking HSCT have had to travel overseas to Mexico, Russia and Israel and bankroll their own private treatment at a cost of around 40-60,000.

It has also been available privately in London since 2017, but with a 100,000 price tag.

A small number of MS patients in England have been able to access the treatment on the NHS, however, because there are clinical trials into HSCT taking place at NHS hospitals in Sheffield and London.

Morna Simpkins, director of MS Society Scotland, said: The decision from SHTG to approve HSCT for the treatment of MS is good news and could help in the development of a clear pathway, for people who could potentially benefit, to access it.

We will push to ensure that this decision leads to real change for people with MS by continuing to engage with other groups to offer the treatments, including HSCT, which are right for them.

READ MORE: Stem cells help mother with MS make 'remarkable' recovery

The SHTG said eligible patients must have equal access to the procedures regardless of where they live, but it is unlikely all health boards will be able to provide it.

The MS Society wants a centre, or centres, of excellence set up where patients from across Scotland can be referred.

Lucy Clarke from the Scottish HSCT Network said the recommendation was "a huge step forward" for people in Scotland living with MS.

Ms Clarke underwent HSCT in Russia and credits it with substantially reversing her disability.

She added: This important decision supports HSCT as a treatment option where other treatments have failed. We will continue to push so that this treatment is available to people in Scotland who need it.

A Scottish Government spokeswoman said: We are grateful to the Scottish Health Technologies Group for this important work.

"NHS Boards are expected to consider their advice on technologies in the planning and provision of its services and clinicians are expected to follow their professional judgement, working within the management structure of their Board.

We will work closely with MS Society Scotland, other third sector bodies and the clinical community to consider what the Technologies Groups findings means for provision in Scotland, including the information that needs to be available to people about eligibility and risks.

Read the original:
Stem cell therapy approved for MS patients in Scotland - HeraldScotland

Posted in Stem Cells | Comments Off on Stem cell therapy approved for MS patients in Scotland – HeraldScotland

Can organoids, derived from stem cells, be used in disease treatments? – The Hindu

Posted: October 31, 2019 at 6:45 pm

The story so far: On Monday, October 21, at Neuroscience 2019, the Society for Neurosciences 49th annual meeting, held in Chicago, U.S., two neuroscientists warned the gathering that fellow scientists are perilously close to crossing the ethical red line of growing mini-brains or organoids in the laboratory that can perceive or feel things. In some cases, scientists have already transplanted such lab-grown brain organoid to adult animals. The transplanted organoid had integrated with the animal brain, grown new neuronal connections and responded to light. Similarly, lung organoid transplanted into mice was able to form branching airways and early alveolar structures. These are seen as a step towards potential humanisation of host animals.

Organoids are a group of cells grown in laboratories into three-dimensional, miniature structures that mimic the cell arrangement of a fully-grown organ. They are tiny (typically the size of a pea) organ-like structures that do not achieve all the functional maturity of human organs but often resemble the early stages of a developing tissue. Most organoids contain only a subset of all the cells seen in a real organ, but lack blood vessels to make them fully functional. In the case of brain organoids, scientists have been able to develop neurons and even make specific brain regions such as the cerebral cortex that closely resemble the human brain. The largest brain organoids that have been grown in the laboratory are about 4 mm in diameter.

Organoids are grown in the lab using stem cells that can become any of the specialised cells seen in the human body, or stem cells taken from the organ or adults cells that have been induced to behave like stem cells, scientifically called induced pluripotent stem cells (iPSC). Stem cells are provided with nutrients and other specific molecules to grow and become cells resembling a specific organ. The growing cells are capable of self-organising into cellular structures of a specific organ and can partly replicate complex functions of mature organs physiological processes to regeneration and being in a diseased state.

Organoids of the brain, small intestine, kidney, heart, stomach, eyes, liver, pancreas, prostate, salivary glands, and inner ear to name a few have already been developed in the laboratory.

Since the use of embryonic stem cells to grow organs of interest has been mired in controversy leading to a ban on such research, researchers have turned to generating organoids using stem cells. Researchers have been successful in generating organoids of increasing complexity and diversity. Since the organoids closely resemble mature tissues, it opens up new vistas. These include studying the complex arrangements of cells in three-dimension and their function in detail, and understanding how cells assemble into organs.

Organoids can be used to study the safety and efficacy of new drugs and also test the response of tissues to existing medicines. Organoids will bring precision medicine closer to reality by developing patient-specific treatment strategies by studying which drugs the patient is most sensitive to. Since the use of animals during drug development studies is becoming increasingly difficult, the focus has been on refining, reducing and replacing them. While scientists have been increasingly using human cell lines and other methods, such alternatives have some inherent limitations they cannot mimic the whole organ system. Organoids are a far superior alternative to cell lines.

Organoids offer new opportunities to studying proteins and genes that are critical for the development of an organ. This helps in knowing how a mutation in a specific gene causes a disease or disorder. In a study in Europe using intestinal organoids from six patients with an intestine disorder, it became possible to identify the mutation in a gene that prevented the formation of a healthy intestine. Researchers have used brain organoids to study how the Zika virus affects brain development in the embryo.

Scientists are already using stem cells taken from tumours to grow organoids that are poised to develop cancer. The ability to grow organoids using cancer stem cells allows researchers to study the genes, proteins and signalling pathways that cancer cells use to develop and grow. They are also using healthy organoids to identify and verify the gene mutations that cause cancer.

In an opinion piece in Nature, scientists argued that the largest brain that has been grown in the laboratory is only 4 mm in diameter and contains only 2-3 million cells. In comparison, an adult human brain measures 1,350 cubic centimetres, and has 86 billion neurons and another 86 billion non-neuronal cells and a similar number of non-neuronal cells. The authors argue that organoids do not have sensory inputs and sensory connections from the brain are limited. Isolated regions of the brain cannot communicate with other brain regions or generate motor signals. They wrote: Thus, the possibility of consciousness or other higher-order perceptive properties [such as the ability to feel distress] emerging seems extremely remote.

Read the original:
Can organoids, derived from stem cells, be used in disease treatments? - The Hindu

Posted in Stem Cells | Comments Off on Can organoids, derived from stem cells, be used in disease treatments? – The Hindu

Page 1,292«..1020..1,2911,2921,2931,294..1,3001,310..»